



ASX / Media Release  
20 June 2022

## Upcoming Presentations to the 15<sup>th</sup> EUNOS Meeting

---

**Invex Therapeutics Ltd (Invex, ASX:IXC, or the Company)** a clinical-stage biopharmaceutical company focused on the development and commercialisation of Presendin™ (sustained release Exenatide) for neurological conditions relating to raised intracranial pressure, today announces several upcoming oral presentations at the 15<sup>th</sup> European Neuro-Ophthalmology Society (EUNOS) Meeting from 20-23 June 2022 in Birmingham, UK. EUNOS is the major society representing and promoting clinical neuro-ophthalmology in Europe.

Professor Alex Sinclair Invex Executive Director and Chief Scientific Officer of Invex commented “Firstly, I am delighted EUNOS 2022 will be held in Birmingham, where I jointly operate a large Idiopathic Intracranial Hypertension (IIH) clinic at the Queen Elizabeth Hospital. In addition, I am particularly pleased our team is presenting at this important neuro-ophthalmology meeting. With reference to our IIH Phase II PRESSURE Trial, throughout 2022 we have presented the important clinical data to our scientific and medical peers, where the response has been overwhelmingly positive and has greatly facilitated discussions relating to participation in our major IIH EVOLVE Phase III clinical trial.”

Dr James L. Mitchell of the Institute of Metabolism and Systems Research, University of Birmingham, UK on behalf of Invex’s Phase II Pressure Trial in IIH will present key findings of this clinical trial with an oral presentation titled *“IIH Pressure: A randomised controlled, trial of the GLP-1 receptor agonist exenatide in idiopathic intracranial hypertension.”*

In addition, Dr Sinclair will deliver an oral presentation as part of the IIH Symposium titled *“Piecing the jigsaw together - new insights to IIH pathophysiology.”*

For more information on EUNOS 2022, please click [here](#).

- ENDS -

***This release dated 20 June 2022 has been authorised for lodgement to ASX by the Board of Directors of Invex Therapeutics.***

---

## For more information, please contact:

### Company/Investors

Dr Thomas Duthy  
Executive Director  
[tduthy@invextherapeutics.com](mailto:tduthy@invextherapeutics.com)  
+61 402 493 727

### Media

Margie Livingston  
Ignite Communications  
[margie@ignitecommunications.com.au](mailto:margie@ignitecommunications.com.au)  
+61 438 661 131

To subscribe to Invex email alerts, please visit [www.invextherapeutics.com](http://www.invextherapeutics.com) and follow us on Twitter **@InvexThera\_ASX**

## About Invex Therapeutics Ltd

---

Invex is a biopharmaceutical company focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised intracranial pressure, such as Idiopathic Intracranial Hypertension (IIH), acute stroke and traumatic brain injury. Invex has trademarked its repurposed Exenatide as Presendin™. [www.invextherapeutics.com](http://www.invextherapeutics.com).

## About Idiopathic Intracranial Hypertension (IIH)

---

IIH features severely raised intracranial pressure which causes disabling daily headaches and can compress the optic nerve. The usual age of onset is 20-30 years, and it is most common in women who are obese. IIH is a rapidly growing orphan indication: its incidence has increased by more than 350% in the last 10 years.

## About Presendin™

---

Presendin™ is a once per week, sub-cutaneous, sustained-release (SR) Exenatide microsphere formulation originally developed by Peptron, Inc. (KOSDAQ: 087010). In September 2021 Invex entered into an exclusive collaboration, manufacturing and supply agreement with Peptron for Presendin™ in IIH for all major markets, with the exception of South Korea.

Exenatide is a small peptide and a synthetic version of the GLP-1 agonist exendin-4, which is currently approved for the treatment of type 2 diabetes. In 2017, Invex received orphan drug designation for Exenatide in IIH from the US Food and Drug Administration and European Medicines Agency.